Is Turn Therapeutics Inc. Common Stock (TTRX) overvalued? · $187.1M cap
Turn Therapeutics Inc. Common Stock (TTRX) is a biotechnology company listed on NASDAQ.
This page asks whether Turn Therapeutics Inc. Common Stock (TTRX) looks expensive on cached numbers — not a short thesis.
No cached income statement for TTRX, so there is no earnings base to call rich or cheap.
TTRX currently screens at market cap $187.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TTRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TTRX stock page for the full model, not this heading.
Not investment advice.